Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Tiumeq

- PMLiVE

BMS drops antiviral research in R&D shake-up

Up to 100 positions set to be lost by the US company’s research shift

EU flag

Europe wants scientific advice to become pluralistic

Commission endeavours to create a new science committee and reject a single advisor model

- PMLiVE

GSK shelves ViiV sale as it lays out growth strategy

Firm now bullish on the HIV joint pharma project’s prospects

Choices, choices: the rapidly evolving HIV treatment landscape

The treatment options for HIV in Europe has seen some revolutionary changes

- PMLiVE

Non-profit calls to revoke Sovaldi’s European patent

Doctors of the World says Gilead is “abusing its patent” to impose unsustainable prices

- PMLiVE

Gilead to open London headquarters

Mayor Boris Johnson makes announcement as part of trip to Boston, US

Gilead makes senior changes

Expanded roles for Andrew Cheng and Taiyin Yang

- PMLiVE

FDA approves BMS’ Evotaz for HIV

 Combines Reyataz with Gilead’s boosting agent cobicistat  

- PMLiVE

Aetna picks Gilead’s hepatitis C drugs

Health insurance firm favours Sovaldi and Harvoni after negotiating discount

- PMLiVE

NICE backs new hepatitis C treatments

But Sovaldi faces funding delay and Olysio not backed in all indications

- PMLiVE

India turns down patent on Gilead’s Sovaldi

Opens market to cheaper rivals for hepatitis C drug

- PMLiVE

Germany gives green light to Viiv’s Triumeq for HIV

But IQWiG recommendation only covers previously untreated adults

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links